Navigation Links
Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
Date:7/1/2011

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

"These encouraging data demonstrating statistically significant pharmacodynamic activity support the potential of ataluren for a significant subset of severely affected CF patients," stated Professor Michael Wilschanski, Director, Pediatric Gastroenterology, Hadassah University Hospital. "The results are important because they suggest that ataluren promotes the production of full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein and addresses the underlying cause of the disorder. Currently available treatments for cystic fibrosis only address symptoms, and new therapies such as ataluren are urgently needed."

Patients with CF lack adequate levels of the CFTR protein, a chloride channel necessary for the normal function of the lungs, pancreas, liver and other organs. In nmCF, an interruption in the genetic code—known as a nonsense mutation—prematurely halts the synthesis of CFTR, causing the protein to be short and non-functioning. Nonsense mutations are categorized as Class I mutations that result in little or no production of the CFTR protein. CF patients with Class I mutations typically experience more severe disease symptoms than those with lower-risk genotypes, including a greater than twofold increased risk of death(1), a higher probability of end-stage lung disease(2), and a higher prevalence of pancreatic insufficiency.(2) It is estimated that nonsense
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ... of its third fiscal quarter 2011 earnings conference call on ... will issue a press release detailing the quarter,s earnings earlier ... along with related slides, will be accessible through BD,s website ...
... Va., July 8, 2011 The Amerigroup Foundation recently ... the Rx Partnership to benefit the Rockbridge Area Free ... organization that works to provide uninsured Virginians with access ... broker to access and distribute free bulk prescription medications ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2
(Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... findings from Fox Chase Cancer Center paint a relatively ... of breast cancers that have spread to the chest ... that grow into the skin, regardless of size and ... as stage III and called "locally advanced" tumors, ... cancer, often with poor survival. Locally advanced breast cancers ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2
... When patients choose to leave the hospital before the ... of inadequately treated medical conditions and the need for ... issue of Mayo Clinic Proceedings . Additionally, the ... predictors and potential interventions to help manage and improve ...
... in the international journal Chest , by Neil ... disease (COPD) who breathed a mix of 60% helium ... to exercise longer and harder than those who breathed ... significant because research has shown that patients who perform ...
... 2009Chemicals present in cranberriesand not the acidity of cranberry ... the cells that line the urinary tract, as documented ... Food , a peer-reviewed journal published by Mary Ann ... free online at www.liebertpub.com/jmf , Urinary tract ...
... Provide Information on Medicare Advantage Special Needs Plans, ... March 9 A series of free seminars ... illness maintain a healthy lifestyle and learn about ... unique needs will be offered during March at ...
... continued growthATLANTA, March 9 Reveille Software(TM) ... grown to 275 customers and expanded its ... itself for continued market growth in helping ... performance management.Reveille,s solution, Reveille Experience and Performance ...
... study show continued, significant relief of depressive symptoms, ... hospitalization and death among ESRD patientsLAWRENCE, Mass., March ... NXTM ), a leading manufacturer of innovative dialysis ... its ongoing FREEDOM study, which show that the ...
Cached Medicine News:Health News:Patients being discharged against medical advice 2Health News:Helium helps lung patients breathe easier 2Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:Seminars Offered to Missouri Seniors With Diabetes and Other Chronic Illnesses 2Health News:Reveille Software Reaches Customer Milestone and Expands Executive Team 2Health News:Reveille Software Reaches Customer Milestone and Expands Executive Team 3Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 2Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 3Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 4
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... The SheerVision FireFly Infinity Light ... most technologically advanced LED light ever ... ,With the FireFly Infinity you'll get ... unrestricted mobility to go whereever your ...
... SICKLEDEX detects the presence of ... requires 2ml of reconstituted solubility buffer and ... of sickle cell hemoglobin control. Each test ... with Saponin, two buffer dispensing caps and ...
... is for use as a sheath fluid ... 70ml bottle of Cytometry Concentrate dilutes to ... Compared to Cubitainers, Streck Cytometry Concentrate reduces ... money without compromising performance. Streck Cytometry Concentrate ...
Medicine Products: